Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 8—August 2024
Research

Detection of Nucleocapsid Antibodies Associated with Primary SARS-CoV-2 Infection in Unvaccinated and Vaccinated Blood Donors

Eduard Grebe1Comments to Author , Mars Stone1, Bryan R. Spencer, Akintunde Akinseye, David Wright, Clara Di Germanio, Roberta Bruhn, Karla G. Zurita, Paul Contestable, Valerie Green, Marion C. Lanteri, Paula Saa, Brad J. Biggerstaff, Melissa M. Coughlin, Steve Kleinman, Brian Custer, Jefferson M. Jones, and Michael P. Busch
Author affiliations: Vitalant Research Institute, San Francisco, California, USA (E. Grebe, M. Stone, C. Di Germanio, R. Bruhn, K.G. Zurita, B. Custer, M.P. Busch); University of California, San Francisco (M. Stone, R. Bruhn, M.C. Lanteri, B. Custer, M.P. Busch); American Red Cross, Rockville, Maryland, USA (B.R. Spencer, P. Saa); Westat, Rockville (A. Akinseye, D. Wright); QuidelOrtho, Rochester, New York, USA (P. Contestable); Creative Testing Solutions, Tempe, Arizona, USA (V. Green, M.C. Lanteri); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (B.J. Biggerstaff); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M.M. Coughlin, J.M. Jones); University of British Columbia, Vancouver, British Columbia, Canada (S. Kleinman)

Main Article

Figure 1

Nucleocapsid antibody signal intensity distributions observed in vaccinated and unvaccinated blood donors after primary SARS-CoV-2 infection, United States, July 2021–December 2022. A) Reactivity of putative serologically identified infections at the first longitudinal sample showing reactivity above the reduced cutoff (gray zone reactivity, S/CO ratio>0.395<1), by vaccination status and variant era (6,555 unvaccinated donors [left] and 22,217 vaccinated donors [right]). B) Reactivity at the first sample collected after self-reported swab-confirmed infection (14 to 180 days postinfection), by vaccination status and variant era (2,751 unvaccinated donors [left] and 8,187 vaccinated donors [right]). Vertical dashed lines indicate the gray zone of nucleocapsid antibodies. O1, January–March 2022; O2, April–June 2022; O3, July–September 2022; O4, October–December 2022. S/CO, signal-to-cutoff ratio.

Figure 1. Nucleocapsid antibody signal intensity distributions observed in vaccinated and unvaccinated blood donors after primary SARS-CoV-2 infection, United States, July 2021–December 2022. A) Reactivity of putative serologically identified infections at the first longitudinal sample showing reactivity above the reduced cutoff (gray zone reactivity, S/CO ratio>0.395<1), by vaccination status and variant era (6,555 unvaccinated donors [left] and 22,217 vaccinated donors [right]). B) Reactivity at the first sample collected after self-reported swab-confirmed infection (14 to 180 days postinfection), by vaccination status and variant era (2,751 unvaccinated donors [left] and 8,187 vaccinated donors [right]). Vertical dashed lines indicate the gray zone of nucleocapsid antibodies. O1, January–March 2022; O2, April–June 2022; O3, July–September 2022; O4, October–December 2022. S/CO, signal-to-cutoff ratio.

Main Article

1These first authors contributed equally to this article.

Page created: June 10, 2024
Page updated: July 09, 2024
Page reviewed: July 09, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external